Trial Profile
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Inaleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms INTRO
- 27 Oct 2022 Planned End Date changed from 1 May 2020 to 1 Oct 2023.
- 27 Oct 2022 Planned primary completion date changed from 1 May 2020 to 1 May 2023.
- 12 Sep 2019 Status changed from not yet recruiting to recruiting.